Congestive heart failure

Renal impairment

History of bariatric surgery (i.e. lap-band, Roux-en-Y or biliopancreatic diversion)

Type I diabetes mellitus

Weight loss \> 10% in the past 6 months

Recurrent nephrolithiasis

Current treatment for seizure disorder

Hepatic cirrhosis

Current use of study medications

Current use of oral estrogen

History of smoking cessation in the past three months

Current cholestasis or malabsorption syndrome

Planned use of any herbal or over-the-counter supplements for weight loss

History of allergic reactions to metformin, topiramate, orlistat or any of ingredients

Medical conditions requiring continuous use of phosphodiesterase inhibitors and/or the inability to withhold phosphodiesterase inhibitors for 48 hours

Participation in another clinical drug study within four weeks prior to this investigation.

Participation in any other weight loss or rigorous exercise program.

Any disease or condition that in the opinion of the investigator may interfere with completion of the study

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

What this study is about